Updated: 1 - The US Food and Drug Administration (FDA) has rejected Capricor's cell therapy for Duchenne muscular dystrophy; the company's stock plummeted.
路透社2026/11/20 23:51Stock information has been added in paragraph 2, with a detailed explanation throughout the article.
Reuters, November 20 - The U.S. Food and Drug Administration (FDA) said on Friday that it rejected Capricor Therapeutics’s experimental cell therapy for a deadly genetic disease that causes muscle wasting, CAPR.O, adding to the series of regulatory setbacks for this biotechnology company.
The company's share price dropped by 72% in after-hours trading.
Previously, Capricor was seeking approval for the therapy, called deramiocel, which aims to maintain upper limb function in patients with Duchenne muscular dystrophy.
The agency said there were serious data integrity concerns in a key clinical trial, meaning the available evidence did not meet approval standards.
Duchenne muscular dystrophy is a fatal genetic disorder that primarily affects boys, leading to progressive muscle weakness, loss of mobility, heart complications, and premature death.
This regulatory rejection is a heavy blow to Capricor, threatening not only its main experimental asset but also casting a shadow over the company’s commercial prospects after several months of efforts—which focused on narrowing the application to improve arm and hand mobility.
Previously, the FDA advisory committee (link) voted 9 to 3 in July, concluding that the evidence at the time did not demonstrate deramiocel’s effectiveness for Duchenne-related cardiomyopathy. Capricor subsequently amended its submission, providing new data supporting a shift in the indication to upper limb function.
(To facilitate non-English speakers, Reuters offers automated translations of its reports into several other languages. As automated translations may contain errors or may not accurately capture the intended context, Reuters does not guarantee the accuracy of automated translation texts and provides them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by the use of automated translation features.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
'Grand Theft Auto VI' Drives Comcast, Charter to Record Traffic
